CN112020359A - 含有抗铂化学保护剂的高渗药物组合物 - Google Patents

含有抗铂化学保护剂的高渗药物组合物 Download PDF

Info

Publication number
CN112020359A
CN112020359A CN201980023532.8A CN201980023532A CN112020359A CN 112020359 A CN112020359 A CN 112020359A CN 201980023532 A CN201980023532 A CN 201980023532A CN 112020359 A CN112020359 A CN 112020359A
Authority
CN
China
Prior art keywords
pharmaceutical composition
platinum
hypertonic pharmaceutical
hypertonic
gelling agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980023532.8A
Other languages
English (en)
Chinese (zh)
Inventor
Q-Y·胡
J·李
石复辛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Decibel Therapeutics Inc
Original Assignee
Decibel Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decibel Therapeutics Inc filed Critical Decibel Therapeutics Inc
Publication of CN112020359A publication Critical patent/CN112020359A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/02—Ammonia; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN201980023532.8A 2018-02-09 2019-02-08 含有抗铂化学保护剂的高渗药物组合物 Pending CN112020359A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862628824P 2018-02-09 2018-02-09
US62/628824 2018-02-09
PCT/US2019/017334 WO2019157370A1 (en) 2018-02-09 2019-02-08 Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent

Publications (1)

Publication Number Publication Date
CN112020359A true CN112020359A (zh) 2020-12-01

Family

ID=67549759

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980023532.8A Pending CN112020359A (zh) 2018-02-09 2019-02-08 含有抗铂化学保护剂的高渗药物组合物

Country Status (12)

Country Link
US (5) US10709732B2 (enExample)
EP (1) EP3749309A4 (enExample)
JP (3) JP7492917B2 (enExample)
KR (1) KR102860981B1 (enExample)
CN (1) CN112020359A (enExample)
AU (1) AU2019218232B2 (enExample)
BR (1) BR112020016059A2 (enExample)
CA (1) CA3090783A1 (enExample)
IL (1) IL276569B2 (enExample)
MX (2) MX2020008323A (enExample)
SG (1) SG11202007595WA (enExample)
WO (1) WO2019157370A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018039375A1 (en) 2016-08-23 2018-03-01 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
BR112020016059A2 (pt) 2018-02-09 2020-12-08 Decibel Therapeutics, Inc. Composições farmacêuticas hipertônicas contendo um agente quimioprotetor anti-platina
IL325122A (en) 2018-02-22 2026-02-01 Akouos Inc Compositions and methods for treating non-age-related hearing impairment in humans
BR112021000021A2 (pt) * 2018-07-03 2021-03-30 Fennec Pharmaceuticals, Inc. Tiossulfato de sódio anidro e formulações do mesmo
US20220054640A1 (en) * 2018-12-11 2022-02-24 Decibel Therapeutics, Inc. Compositions and methods for the delivery of therapeutic agents across the round window membrane
US10813947B1 (en) 2019-05-31 2020-10-27 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents
WO2020256548A1 (en) * 2019-06-19 2020-12-24 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Sodium thiosulfate gel for preventing or reducing hearing loss
CN114845721A (zh) * 2019-10-30 2022-08-02 奥德纳米有限公司 用于药物诱导的耳毒性的耳用制剂
CA3168055A1 (en) 2020-02-21 2021-08-26 Emmanuel John Simons Compositions and methods for treating non-age-associated hearing impairment in a human subject
US20260027327A1 (en) 2024-07-26 2026-01-29 Regeneron Pharmaceuticals, Inc. Otic drug delivery system and methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090306225A1 (en) * 2008-04-21 2009-12-10 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US8496973B2 (en) * 2009-07-08 2013-07-30 Hope Medical Enterprises, Inc. Sodium thiosulfate-containing pharmaceutical compositions
US9427472B2 (en) * 2008-07-21 2016-08-30 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649621B2 (en) 1997-12-16 2003-11-18 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US6497902B1 (en) 1999-12-01 2002-12-24 The Regents Of The University Of Michigan Ionically crosslinked hydrogels with adjustable gelation time
KR20030014208A (ko) 2000-04-26 2003-02-15 오레곤 헬스 사이언시즈 유니버시티 티올계 화학보호제 화합물의 투여
EP1404689A1 (en) * 2001-07-02 2004-04-07 Debiopharm S.A. Oxaliplatin active substance with a very low content of oxalic acid
US7790699B2 (en) 2004-10-12 2010-09-07 Fmc Biopolymer As Self-gelling alginate systems and uses thereof
CA2620374C (en) 2005-09-28 2012-12-11 Thomas Meyer Pharmaceutical compositions for the treatment of inner ear disorders
WO2008056822A1 (en) 2006-11-09 2008-05-15 Takeda Pharmaceutical Company Limited Pharmaceutical composition comprising a dihydrobenzofuranyl isoindoline and a lipophilic component
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US20100016450A1 (en) 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
EP3501521A1 (en) 2011-02-18 2019-06-26 Otonomy, Inc. Prevention of and recovery from drug-induced ototoxicity
US10130514B2 (en) 2011-09-26 2018-11-20 Incube Labs, Llc System and method for delivery of a therapeutic agent to the inner ear
FR2992861B1 (fr) * 2012-07-09 2014-10-17 Probionov Utilisation de thiosulfate pour potentialiser l'effet anti-pathogene des lactobacilles
JP7074663B6 (ja) * 2015-05-28 2022-08-01 ベイラー カレッジ オブ メディスン グルタチオンレベルを改善するためのｎ－アセチルシステイン及びグリシンの補給の効果
AU2016304585B2 (en) 2015-08-05 2023-04-06 Children's Medical Center Corporation Compositions with permeation enhancers for drug delivery
US20190038756A1 (en) 2016-02-10 2019-02-07 Cocoon Biotech Inc. Compositions including benzenesulfonamide-containing non-steroidal anti-inflammatory drugs, silk fibroin, and a gelling agent and uses thereof
EP3478269A4 (en) 2016-06-29 2020-04-08 Otonomy, Inc. OTIC FORMULATIONS BASED ON TRIGLYCERIDES AND THEIR USES
EP3570826A4 (en) 2017-01-19 2020-09-23 Otologic Pharmaceutics, Inc. N-ACETYLCYSTEIN FORMULATIONS AND THEIR USES
US10596190B2 (en) 2017-11-29 2020-03-24 Oregon Health & Science University Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy
WO2019118330A1 (en) 2017-12-12 2019-06-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Thermoresponsive hydrogel containing polymer microparticles for controlled drug delivery to the ear
US11918653B2 (en) 2017-12-22 2024-03-05 Dompé Farmaceutici S.P.A. Triglyceride otic formulations and uses thereof
US10946443B2 (en) 2018-01-08 2021-03-16 Hamilton Sundstrand Corporation Removal of unfused powder from an additive-manufactured part using piezoelectric transducers
WO2019140012A1 (en) 2018-01-09 2019-07-18 Otonomy, Inc. Growth factor otic formulations
WO2019154895A1 (en) 2018-02-08 2019-08-15 Strekin Ag Gel formulation for preventing or treating hearing loss
BR112020016059A2 (pt) 2018-02-09 2020-12-08 Decibel Therapeutics, Inc. Composições farmacêuticas hipertônicas contendo um agente quimioprotetor anti-platina
US20210186943A1 (en) 2018-04-25 2021-06-24 Otonomy, Inc. Otic formulations for drug-induced ototoxicity
IT201800006566A1 (it) 2018-06-21 2019-12-21 Composizione per prevenire e trattare disordini uditivi e vestibolari
BR112021000021A2 (pt) 2018-07-03 2021-03-30 Fennec Pharmaceuticals, Inc. Tiossulfato de sódio anidro e formulações do mesmo
US10813947B1 (en) 2019-05-31 2020-10-27 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents
WO2020256548A1 (en) 2019-06-19 2020-12-24 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Sodium thiosulfate gel for preventing or reducing hearing loss

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090306225A1 (en) * 2008-04-21 2009-12-10 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US9427472B2 (en) * 2008-07-21 2016-08-30 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
US8496973B2 (en) * 2009-07-08 2013-07-30 Hope Medical Enterprises, Inc. Sodium thiosulfate-containing pharmaceutical compositions

Also Published As

Publication number Publication date
BR112020016059A2 (pt) 2020-12-08
SG11202007595WA (en) 2020-09-29
JP2026119177A (ja) 2026-07-16
EP3749309A1 (en) 2020-12-16
US20210308176A1 (en) 2021-10-07
CA3090783A1 (en) 2019-08-15
US20200338119A1 (en) 2020-10-29
MX2020008323A (es) 2020-10-14
US11857567B2 (en) 2024-01-02
MX2023001963A (es) 2023-02-23
WO2019157370A1 (en) 2019-08-15
US20240350533A1 (en) 2024-10-24
JP7492917B2 (ja) 2024-05-30
US11071751B2 (en) 2021-07-27
KR102860981B1 (ko) 2025-09-18
AU2019218232A1 (en) 2020-09-24
IL276569B2 (en) 2023-06-01
AU2019218232B2 (en) 2024-12-19
JP2024098070A (ja) 2024-07-19
IL276569A (en) 2020-09-30
US20250381219A1 (en) 2025-12-18
JP2021513558A (ja) 2021-05-27
US20190336524A1 (en) 2019-11-07
EP3749309A4 (en) 2021-12-08
US10709732B2 (en) 2020-07-14
KR20200129107A (ko) 2020-11-17

Similar Documents

Publication Publication Date Title
US11857567B2 (en) Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent
ES2524994T3 (es) Composiciones farmacéuticas para el tratamiento de trastornos del oído interno.
Borden et al. Hyaluronic acid hydrogel sustains the delivery of dexamethasone across the round window membrane
US20240226141A9 (en) Methods of otoprotection against platinum-based antineoplastic agents
US20170071938A1 (en) Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
CN116211799B (zh) 一种局麻药复合物混悬剂
AU2020284122B2 (en) Methods of otoprotection against platinum-based antineoplastic agents
CA3142153C (en) Methods of otoprotection against platinum-based antineoplastic agents
BR122023025163A2 (pt) Composições farmacêuticas hipertônicas contendo um agente quimioprotetor antiplatina, seu uso e seu método de preparação
US12233157B1 (en) Hydrogel formulations and methods and devices for administration of the same
US12343916B2 (en) Anti-adhesive hydrogel composition
WO2026024285A1 (en) Hydrogel formulations and methods and devices for administration of the same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination